KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Intangibles: 2020-2024

Historic Change in Intangibles for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Dec 2024 value amounting to $3.4 million.

  • Recursion Pharmaceuticals' Change in Intangibles changed negligibly% to $350,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $3.8 million, marking a year-over-year increase of 321.63%. This contributed to the annual value of $3.4 million for FY2024, which is 461.14% up from last year.
  • As of FY2024, Recursion Pharmaceuticals' Change in Intangibles stood at $3.4 million, which was up 461.14% from $597,000 recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Change in Intangibles ranged from a high of $3.4 million in FY2024 and a low of $300,000 during FY2022.
  • In the last 3 years, Recursion Pharmaceuticals' Change in Intangibles had a median value of $597,000 in 2023 and averaged $1.4 million.
  • Data for Recursion Pharmaceuticals' Change in Intangibles shows a peak YoY surged of 461.14% (in 2024) over the last 5 years.
  • Yearly analysis of 4 years shows Recursion Pharmaceuticals' Change in Intangibles stood at $904,000 in 2020, then reached $300,000 in 2022, then soared by 99.00% to $597,000 in 2023, then surged by 461.14% to $3.4 million in 2024.